Filing Analysis
Oncolytics Biotech Inc. issued a press release on June 16, 2026, announcing a new patent concerning the manufacturing of pelareorep and providing updates to its intellectual property portfolio.
📋 Key Facts
- The company announced a new patent specifically related to the manufacturing of pelareorep.
- The filing includes updates regarding the broader intellectual property portfolio for pelareorep.
- The information was furnished via a press release (Exhibit 99.1) on June 16, 2026.
Oncolytics Biotech Inc. announced the appointment of John McAdory as Chief Operating Officer and Stephen Glover as a ninth member of the Board of Directors, effective June 1, 2026.
📋 Key Facts
- John McAdory appointed as COO on June 1, 2026; he previously served as EVP of Strategy and Operations since January 2026.
- Stephen Glover appointed as a director on June 1, 2026, bringing extensive biopharma experience including roles at ZyVersa Therapeutics and Ambrx Biopharma.
- Stephen Glover was granted an option to purchase 96,000 shares of common stock, vesting in equal installments of 32,000 shares over three years.
- Mr. McAdory's background includes clinical operations leadership at CG Oncology, Inc. and SillaJen, Inc.
- Mr. Glover's track record includes guiding Ambrx Biopharma through a ~$2 billion acquisition by Johnson & Johnson.
Oncolytics Biotech Inc. issued a press release on June 1, 2026, announcing initial preclinical data for its lead candidate, pelareorep, in combination with RAS inhibitor modalities.
📋 Key Facts
- The company released initial preclinical data for pelareorep combined with RAS inhibitor modalities.
- The company announced plans to conduct additional studies evaluating pelareorep with multiple RAS-targeted agents.
- The filing is categorized under Item 8.01 (Other Events) and the information is 'furnished' rather than 'filed'.
Oncolytics Biotech Inc. announced that it will present translational data from its GOBLET and AWARE-1 clinical studies at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will describe pelareorep's mechanism of action and its effect on the activation of the innate and adaptive immune systems.
📋 Key Facts
- Filing date and event date of May 22, 2026.
- The company will present clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- Data includes translational findings from the GOBLET and AWARE-1 studies.
- The data focuses on pelareorep's mechanism of action and its activation of the innate and adaptive immune systems.
- The announcement was disseminated via a press release filed as Exhibit 99.1.
Oncolytics Biotech Inc. issued a press release on May 4, 2026, providing updates on its REO 022 clinical study. The study focuses on treatments for metastatic colorectal cancer.
📋 Key Facts
- The company announced updates for the REO 022 clinical study on May 4, 2026.
- The study targets metastatic colorectal cancer.
- The disclosure was filed under Item 8.01 (Other Events) and includes a press release as Exhibit 99.1.
- The filing was signed by CFO Kirk Look.
Oncolytics Biotech Inc. announced it has reached an agreement with the U.S. FDA regarding the design of a controlled randomized pivotal study. The study will focus on treating squamous cell carcinoma of the anal canal.
📋 Key Facts
- The company announced FDA alignment on April 27, 2026.
- The planned study is a controlled randomized pivotal trial.
- The target indication is squamous cell carcinoma of the anal canal.
- The announcement was filed under Item 8.01 (Other Events).
Oncolytics Biotech Inc. announced an upcoming Type C meeting with the FDA to discuss the design of a single-arm pivotal study for its lead candidate, pelareorep. The study aims to evaluate pelareorep in combination with a checkpoint inhibitor for the treatment of squamous cell anal carcinoma (SCAC).
📋 Key Facts
- The company has scheduled a Type C meeting with the U.S. FDA.
- The meeting will focus on the design of a single-arm pivotal study for pelareorep.
- The target indication is squamous cell anal carcinoma (SCAC).
- The treatment regimen involves a combination of pelareorep and a checkpoint inhibitor.
- The announcement was made via a press release on April 6, 2026.
Oncolytics Biotech Inc. entered into an Open Market Sale Agreement with Jefferies LLC to establish an At-The-Market (ATM) offering of up to $75.0 million. The company intends to use the proceeds to fund the clinical development of its lead candidate, pelareorep, and for general corporate purposes.
🚩 Red Flags
- Potential for significant shareholder dilution if the full $75.0 million is utilized, which is common for micro-cap biotech firms needing to fund clinical trials.
📋 Key Facts
- Agreement entered into on April 6, 2026, with Jefferies LLC as the sales agent.
- The company may sell common stock with an aggregate offering price of up to $75.0 million.
- Jefferies LLC will receive a commission of up to 3.0% of the gross proceeds from sales.
- The offering is conducted under a shelf registration statement on Form S-3 (File No. 333-294811) effective as of April 3, 2026.
- Proceeds are earmarked for the clinical development of pelareorep, R&D expenses, and working capital.
Oncolytics Biotech completed its redomestication from British Columbia, Canada, to Nevada, USA, effective March 31, 2026. This structural change involved adopting new Articles of Incorporation, Bylaws, and a significantly dilutive 2026 Incentive Award Plan.
🚩 Red Flags
- Significant potential dilution from the 2026 Incentive Award Plan's 6.5 million share pool and 6% annual evergreen increase.
- Implementation of robust anti-takeover measures, including 'blank check' preferred stock and restricted stockholder ability to act by written consent.
- Supermajority requirements (two-thirds) for director removal and bylaw amendments make management changes more difficult.
- Exclusive forum provisions in the new Bylaws restrict litigation to Nevada courts, potentially increasing costs for shareholder claims.
📋 Key Facts
- Completed redomestication from British Columbia to Nevada on March 31, 2026.
- Adopted the 2026 Incentive Award Plan with an initial pool of 6,500,000 shares.
- The 2026 Plan includes an 'evergreen' provision allowing an annual increase of up to 6% of outstanding common stock starting January 1, 2027.
- New CUSIP number 68237V 103 and ISIN US68237V1035 effective April 1, 2026.
- Entered into new indemnification and advancement agreements with all executive officers and directors.
- Governance changes include the authorization of 'blank check' preferred stock and a two-thirds supermajority requirement for stockholders to remove directors or amend bylaws.
Oncolytics Biotech Inc. has initiated a two-step redomestication process, moving its jurisdiction from Alberta, Canada, to British Columbia, Canada, effective March 17, 2026. The company plans to complete the second step by domesticating in Nevada, USA, on March 31, 2026, which will result in a change of governing law and security identifiers.
🚩 Red Flags
- Material modification of shareholder rights as the company moves from Canadian (ABCA/BCBCA) to US (Nevada) corporate law.
- Complex two-step legal restructuring involving multiple jurisdictions in a short timeframe.
📋 Key Facts
- Shareholders approved the redomestication at a Special Meeting on January 15, 2026.
- Step 1: Completed 'Continuance' from Alberta to British Columbia on March 17, 2026.
- Step 2: Planned 'Domestication' to Nevada, USA, scheduled for March 31, 2026.
- Effective April 1, 2026, the CUSIP will change to 68237V 103 and the ISIN to US68237V1035.
- Common shares will transition to Nevada common stock with a par value of $0.001 per share.
- The company's ticker symbol 'ONCY' will remain unchanged on the Nasdaq.
Oncolytics Biotech announced the acceptance of two clinical trial abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting. The presentations will feature data from the GOBLET study in pancreatic cancer and the AWARE-1 study in breast cancer.
📋 Key Facts
- Filing date: March 19, 2026.
- Two abstracts accepted for the AACR Annual Meeting.
- Data includes Cohort 1 of the GOBLET study focusing on metastatic pancreatic ductal adenocarcinoma.
- Data includes the AWARE-1 study focusing on breast cancer patients.
- The filing is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-289819).
Oncolytics Biotech Inc. announced the launch of REO 033, a randomized clinical study evaluating treatments for second-line RAS-mutant microsatellite stable (MSS) metastatic colorectal cancer. The announcement was made via a press release on March 2, 2026, and is incorporated into the company's existing shelf registration.
📋 Key Facts
- Launch of randomized study REO 033 announced on March 2, 2026
- Study targets second-line RAS-mutant microsatellite stable (MSS) metastatic colorectal cancer patients
- Press release attached as Exhibit 99.1
- The filing is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-289819)
Oncolytics Biotech announced a strategic shift to prioritize registrational or registration-enabling studies specifically for colorectal and anal cancer. Concurrently, the company has completed enrollment for its GOBLET gastrointestinal cancer study.
📋 Key Facts
- Prioritizing registrational studies in colorectal and anal cancer
- Concluded enrollment in the GOBLET gastrointestinal cancer study
- Filing is incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-289819)
- Press release dated February 24, 2026